{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:38:29Z","timestamp":1784864309707,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ejca.2015.11.009","type":"journal-article","created":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T11:46:22Z","timestamp":1451735182000},"page":"104-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Single-nucleotide polymorphism in the 5-\u03b1-reductase gene ( SRD5A2 ) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors"],"prefix":"10.1016","volume":"54","author":[{"given":"Hink","family":"Boer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico-Derk L.","family":"Westerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"Altena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Nuver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A. Janneke","family":"Dijck-Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"van Faassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Klont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido P.","family":"Kema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop D.","family":"Lefrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Marike","family":"Boezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andries J.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coby","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jourik A.","family":"Gietema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ejca.2015.11.009_bib1","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/jnci\/djq216","article-title":"Testicular cancer survivorship: research strategies and recommendations","volume":"102","author":"Travis","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejca.2015.11.009_bib2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/annonc\/mds579","article-title":"Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer","volume":"24","author":"Beyer","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2015.11.009_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1200\/JCO.2005.02.7193","article-title":"Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer","volume":"24","author":"van den Belt-Dusebout","year":"2006","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.ejca.2015.11.009_bib4","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1200\/JCO.2006.10.5296","article-title":"Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer","volume":"25","author":"van den Belt-Dusebout","year":"2007","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2015.11.009_bib5","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1200\/JCO.2005.02.176","article-title":"The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer","volume":"23","author":"Nuver","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2015.11.009_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/annonc\/mdl372","article-title":"Components of the metabolic syndrome in long-term survivors of testicular cancer","volume":"18","author":"Haugnes","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2015.11.009_bib7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mds527","article-title":"Early development of the metabolic syndrome after chemotherapy for testicular cancer","volume":"24","author":"de Haas","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2015.11.009_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/bjc.2013.226","article-title":"Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors","volume":"109","author":"Willemse","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2015.11.009_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/ije\/dyq158","article-title":"Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies","volume":"40","author":"Brand","year":"2011","journal-title":"Int J Epidemiol"},{"issue":"12","key":"10.1016\/j.ejca.2015.11.009_bib10","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1093\/eurheartj\/ehq009","article-title":"Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20\u201379","volume":"31","author":"Haring","year":"2010","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ejca.2015.11.009_bib11","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1210\/jc.2013-1970","article-title":"Beneficial and adverse effects of testosterone on the cardiovascular system in men","volume":"98","author":"Ruige","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ejca.2015.11.009_bib12","doi-asserted-by":"crossref","first-page":"e100409","DOI":"10.1371\/journal.pone.0100409","article-title":"Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies","volume":"9","author":"Brand","year":"2014","journal-title":"PLoS One"},{"issue":"1-2","key":"10.1016\/j.ejca.2015.11.009_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mce.2008.10.035","article-title":"Androgen metabolism in adipose tissue: recent advances","volume":"301","author":"Blouin","year":"2009","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"10.1016\/j.ejca.2015.11.009_bib14","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1530\/JOE-12-0455","article-title":"Testosterone: a metabolic hormone in health and disease","volume":"217","author":"Kelly","year":"2013","journal-title":"J Endocrinol"},{"issue":"3","key":"10.1016\/j.ejca.2015.11.009_bib15","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/JOE-12-0582","article-title":"Testosterone: a vascular hormone in health and disease","volume":"217","author":"Kelly","year":"2013","journal-title":"J Endocrinol"},{"issue":"2","key":"10.1016\/j.ejca.2015.11.009_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1470-2045(09)70287-6","article-title":"The metabolic syndrome in cancer survivors","volume":"11","author":"de Haas","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2015.11.009_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0302-2838(03)00263-X","article-title":"Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer","volume":"44","author":"Nord","year":"2003","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ejca.2015.11.009_bib18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2013.51.2715","article-title":"Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors","volume":"32","author":"Sprauten","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2015.11.009_bib19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1206168","article-title":"Gonadal steroids and body composition, strength, and sexual function in men","volume":"369","author":"Finkelstein","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejca.2015.11.009_bib20","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/humrep\/deu274","article-title":"Genetic variations associated with the effect of testicular cancer treatment on gonadal hormones","volume":"29","author":"Aschim","year":"2014","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.ejca.2015.11.009_bib21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00008571-200007000-00004","article-title":"Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II","volume":"10","author":"Makridakis","year":"2000","journal-title":"Pharmacogenetics"},{"issue":"8","key":"10.1016\/j.ejca.2015.11.009_bib22","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"18","author":"Meinardi","year":"2000","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2015.11.009_bib23","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ejca.2015.11.009_bib24","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ejca.2003.12.012","article-title":"Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer","volume":"40","author":"Nuver","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2015.11.009_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0378-4347(00)80683-0","article-title":"Profiling steroid hormones and urinary steroids","volume":"379","author":"Shackleton","year":"1986","journal-title":"J Chromatogr"},{"issue":"7","key":"10.1016\/j.ejca.2015.11.009_bib26","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/jms.1457","article-title":"Factors influencing the steroid profile in doping control analysis","volume":"43","author":"Mareck","year":"2008","journal-title":"J Mass Spectrom"},{"key":"10.1016\/j.ejca.2015.11.009_bib27","unstructured":"NCBI. dbSNP: rs523349. http:\/\/www.ncbi.nlm.nih.gov\/SNP\/snp_ref.cgi?rs=523349."},{"key":"10.1016\/j.ejca.2015.11.009_bib28","unstructured":"NCBI. dbSNP: rs9282858. http:\/\/www.ncbi.nlm.nih.gov\/SNP\/snp_ref.cgi?rs=9282858."},{"issue":"1","key":"10.1016\/j.ejca.2015.11.009_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/cen.12407","article-title":"Differential associations of testosterone, dihydrotestosterone and oestradiol with physical, metabolic and health-related factors in community-dwelling men aged 17\u201397 years from the Busselton Health Survey","volume":"81","author":"Yeap","year":"2014","journal-title":"Clin Endocrinol Oxf"},{"issue":"5","key":"10.1016\/j.ejca.2015.11.009_bib30","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1007\/s11033-012-2434-x","article-title":"Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis","volume":"40","author":"Li","year":"2013","journal-title":"Mol Biol Rep"},{"issue":"12","key":"10.1016\/j.ejca.2015.11.009_bib31","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/clinchem\/35.12.2281","article-title":"Steroid profile for urine: reference values","volume":"35","author":"Weykamp","year":"1989","journal-title":"Clin Chem"},{"issue":"7","key":"10.1016\/j.ejca.2015.11.009_bib32","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/pros.22792","article-title":"Androgenic biomarker prof|ling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry","volume":"74","author":"Wilton","year":"2014","journal-title":"Prostate"},{"issue":"B","key":"10.1016\/j.ejca.2015.11.009_bib33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jsbmb.2014.08.015","article-title":"A sensitive, simple and robust LC-MS\/MS method for the simultaneous quantification of seven androgen- and estrogen-related steroids in postmenopausal serum","volume":"144","author":"Ke","year":"2014","journal-title":"J Steroid Biochem Mol Biol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915010394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915010394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T12:57:48Z","timestamp":1600001868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915010394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":33,"alternative-id":["S0959804915010394"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.11.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-nucleotide polymorphism in the 5-\u03b1-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}